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I had always the opinion, 
that there is something more important than gold. 
Glass, for example, I consider for more important 





Many people said that is the intellect that does a great scientist. 
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The aim of this work was to develop and characterize new calcium phosphate glass 
ceramics that would degrade in a controlled manner in the body environment, which could 
ultimately be used in regenerative surgery.  
Two glasses MK5 (45CaO-45P2O5-5MgO-5K2O, mol%) and MT13 (45CaO-37P2O5-
5MgO-13TiO2, mol%) were prepared in the meta-, pyro- and orthophosphate regions and 
crystallized to obtain MK5B and MT13B glass ceramics, respectively. The MK5B glass 
ceramic was prepared by controlled crystallization of base glass blocks whereas MT13B 
was prepared by sintering and crystallization of base glass powder discs. As a result of the 
heat treatment used to convert glass into glass ceramic, four crystalline phases were 
precipitated in the glassy matrix: KCa(PO3)3, β-Ca(PO3)2, β-Ca2P2O7 and Ca4P6O19 phases 
for MK5B and CaTi4(PO4)6, TiP2O7, α- and β-Ca2P2O7 phases for MT13B. These two 
glass ceramics showed distinct in vitro and in vivo behaviour, which could be attributed to 
the different crystalline phases that were found in their microstructure.  
The in vitro biological performance of the MK5B and MT13B glass-ceramics was assessed 
by direct cell culture methods using MG63 osteoblast-like cells and human bone marrow 
osteoblastic cells. The results demonstrated that the cells were able to adhere and 
proliferate on both MK5B and MT13B surfaces, but the latter showed an enhanced 
biological performance. Experimental findings demonstrated that the MT13B glass 
ceramic had a stable surface throughout the experiment time whereas MK5B had a highly 
unstable surface with dissolution/precipitation processes occurring throughout the culture 
time, causing an initial inhibition on cell attachment and subsequent proliferation. These 
differences might be attributed to the significant differences in the surface degradation, 
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which was directly correlated to the crystalline phase composition. Both glass ceramics 
were composed of distinct but relatively soluble phases, except the relatively insoluble 
CaTi4(PO4)6 phase, which jointly with the residual glassy phase led to each glass ceramic 
having a unique degradation behaviour. 
The in vivo biological response using a rabbit model showed that MT13B and MK5B had 
different in vivo degradation behaviour, however both materials demonstrated 
osteoconductive behaviour. The higher degradation rate observed in MK5B compared to 
MT13B caused a delay in new bone formation, which might be overcome for longer 
implantation periods.   
 
The results demonstrated that the initial composition of mother glass used and the heat 
treatments applied were efficient in preparing glass ceramic biomaterials. This work also 
showed that by modifying the initial composition of the mother glass as well as using 
different heat treatment cycles, significant changes in the microstructure and properties 
could be achieved. Therefore, glass ceramics materials with significant different 









O presente trabalho teve como objectivo desenvolver e caracterizar novos vidros cerâmicos 
de fosfato de cálcio, com degradação controlada em ambiente fisiológico, tendo em vista a 
sua utilização em medicina regenerativa.  
Foram preparados dois vidros, MK5 (45CaO-45P2O5-5MgO-5K2O, %mol) e MT13 
(45CaO-37P2O5-5MgO-13TiO2, %mol) na região meta-, piro- e ortofosfato, sendo 
posteriormente convertidos nos vidros cerâmicos MK5B e MT13B através de tratamento 
térmico. O MK5B foi obtido por cristalização controlada de amostras de vidro, enquanto o 
MT13B foi obtido por sinterização e cristalização de pós de vidro. Como resultado dos 
tratamentos térmicos, quatro fases cristalinas foram precipitadas na matriz vítrea, i.e. 
KCa(PO3)3, β-Ca(PO3)2, β-Ca2P2O7 e Ca4P6O19 no vidro cerâmico MK5B, e CaTi4(PO4)6, 
TiP2O7, α- e β-Ca2P2O7 no vidro cerâmico MT13B. Estes dois vidros cerâmicos 
apresentaram comportamentos distintos quer em ensaios in vitro quer in vivo, os quais 
devem ser atribuídos às diferentes fases cristalinas presentes nas respectivas 
microestruturas. 
O comportamento biológico in vitro foi analisado pelo método de contacto directo com 
células, tendo-se utilizado a linha celular osteosarcoma MG63 e células osteoblásticas 
humanas. Os resultados mostraram que as células aderiram e proliferaram na superfície dos 
vidros cerâmicos MK5B e MT13B. O vidro cerâmico MT13B apresentou uma superfície 
estável ao longo do tempo de cultura, enquanto que o vidro cerâmico MK5B apresentou 
uma superfície altamente instável, resultante de fenómenos de dissolução/precipitação 
superficial, o que conduziu a uma inibição inicial na adesão das células e na subsequente 
proliferação. Esta diferença de comportamentos foi relacionada com a composição fásica 
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dos dois materiais. Os vidros cerâmicos MK5B e MT13B são constituídos por fases 
cristalinas relativamente solúveis no ambiente fisiológico, com excepção da fase 
CaTi4(PO4)6 que é praticamente insolúvel. 
O comportamento biológico in vivo dos dois vidros cerâmicos foi avaliado através de 
ensaios de cirurgia experimental, utilizando o coelho como modelo animal. Ambos 
materiais apresentaram comportamento bioactivo, embora com algumas diferenças 
acentuadas. A alta taxa de degradação do vidro cerâmico MK5B pareceu causar um atraso 
na formação óssea inicial, condicionando o comportamento biológico in vivo deste 
material. 
 
Este trabalho demonstrou que modificando a composição inicial do vidro e o ciclo de 
tratamento térmico, induzem-se alterações significativas no microestrutura e propriedades 
físico-químicas e biológicas dos materiais. Vidros cerâmicos com taxas de degradação 
significativamente diferentes podem ser obtidos, os quais são susceptíveis de abranger um 




















L’objectif de ce travail a été le développement et la caractérisation de nouvelles 
céramiques de verre et de phosphate de calcium en cours de dégradation controlée dans le 
corps humain, destinées à une utilisation en chirurgie régénérative. 
Deux verres, MK5 (45CaO-45P2O5-5MgO-5K2O, mol%) et MT13 (45CaO-37P2O5-
5MgO-13TiO2, mol%), sont  préparés dans les régions méta-, pyro- et orthophosphate, et 
cristallisés afin d’obtenir respectivement les vitro-céramiques MK5B et MT13B. MK5B 
est préparée par cristallisation controlée de bloques de verre basique, tandis que la MT13B 
est préparée par sintérisation et cristallisation de disques de poudres du verre basique. 
Les résultats des traitements thérmiques utilisés pour transformer les verres en vitro-
céramiques montrent  quatre phases cristallines précipitées sur la matrice vitreuse: 
KCa(PO3)3, β-Ca(PO3)2, β-Ca2P2O7 et Ca4P6O19 dans le cas de MK5B et CaTi4(PO4)6, 
TiP2O7, α- et β-Ca2P2O7 dans le cas de MT13B. Ces deux vitro-céramiques présentent des 
comportements différents a la fois in vitro et in vivo. Ceci peut être attribué à plusieurs 
phases cristallines présentes dans leurs microstructures. 
Le potentiel ostéogénique de MK5B et de MT13B a été évalué in vitro en utilisant les 
cellules ostéoblastique de la lignée MG63 et les cellules stromales de moelle osseuse. Les 
résultats ont démontré que les cellules sont capables d’adhérer et de proliférer sur les deux 
types de vitro-céramiques. Cependant, MT13B montre une meilleur adhésion et 
prolifération. Les résultats expérimentaux ont prouvé que la vitro-céramique MT13B 
présente une surface stable pendant toute la durée des expériences, alors que MK5B a une 
surface assez instable, oú des processus de dissolution/ précipitation pouvaient avoir lieu 
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pendant toute la durée de la période de culture provoquant une inibition initiale de 
l’attachement des cellules et de leur prolifération. Ces différences peuvent être attribuées 
au changement de comportement qui existe au cours la dégradation de surface. Ce 
comportement est directement lié à la composition chimique des phases cristallines. Les 
deux vitro-céramiques sont composées de phases relativement solubles bien que 
différentes, à l’exception de CaTi4(PO4)6 dont la présence, avec d’autres phases vitreuses 
résiduelles, rend unique le comportement de dégradation de chacune des vitro-céramiques. 
Les études in vivo chez le modèle lapin ont démontré que MT13B et MK5B ont des 
niveaux de dégradations différents, même si tout les deux sont ostéoconducteurs. Un  taux 
de dégradation plus élevé a été observé chez MK5B, en comparaison avec celui de MT13B 
ce qui a provoqué un retardement de la formation d’os nouveau. Ce délai peut être annulé 
lors des périodes d’implantation plus longues.  
 
Les résultats ont démontré que la composition initiale du verre original utilisé et le 
traitement thérmique appliqué sont éfficaces pour la préparation de biomatériaux vitro-
céramiques. Ce travail a aussi montré que par modification de la composition du verre 
original ou par changement de traitement thérmique on peut obtenir des microstructures et 
des proprietés assez différentes. Il est donc possible de postuler que les vitro-ceramiques 
avec des niveaux de dégradation différents peuvent être préparées pour plusieurs 







Aim and structure of the thesis 
 
In this work it was attempted to develop and characterize calcium phosphate glass 
ceramics materials with controlled degradation behaviour to be used as bone scaffolds for 
regenerative surgery applications. Two glasses in the CaO-P2O5-MgO system with the 
incorporation of K2O and TiO2 oxides were used as a starting point to prepare glass 
ceramics with different degradation rates. The glass ceramic MK5B (45CaO-45P2O5-
5MgO-5K2O, mol %) was shown to be highly resorbable whereas the glass MT13B 
(45CaO-37P2O5-5MgO-13TiO2, mol %) was much less resorbable as a consequence of the 
crystalline phases precipitated in the mother glass matrix during the heat treatment. 
 
This thesis is composed of four chapters. Chapter 1 consists of a brief overview of the 
literature, and is organised into four divisions: bone tissue, bone grafts, glasses and glass 
ceramics.  
 
Chapters 2 and 3 describe the experimental part of the work. Each chapter is prepared 
using a compilation of work already published and accepted as papers in international 
refereed journals and in international conferences. 
 
In chapter 2 the preparation and physicochemical characterization of the calcium 
phosphate glass ceramics MK5B and MT13B is described. MK5B was prepared by two 
heat treatment steps applied to block glass samples and MT13B by sintering discs of glass 
powder. The composition of the crystalline phases precipitated in the glassy matrix as a 
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result of heat treatments at different temperatures was determined by X-ray diffraction and 
the sequence of phase crystallization was studied using in situ high temperature X-ray 
diffraction (HT-XRD) analysis. The glass ceramics were also characterized using 
FTIR/Raman and X-ray photoelectron spectroscopy.  
The in vitro acellular degradation studies of glass ceramics were performed to asses their 
resorbability potential according to standard ISO 10993:14 - Biological evaluation of 
medical devices - Part 14: Identification and quantification of degradation products from 
ceramics. This standard protocol that was used for the chemical degradation studies 
consisted of two tests. The first test consisted of an extreme soaking solution conducted at 
pH 3.0 uses a citric acid buffer solution that mimics the acid environment produced by 
osteoclasts. The second test simulates a more frequently encountered in vivo pH 7.4 using 
Tris[hydroxymethyl]aminomethane-HCl (TRIS-HCl) buffer. The tests were performed at 
37ºC for up to 6 weeks. The weight loss and ions released were evaluated as a function of 
degradation time.  
 
In chapter 3 the biological evaluation of the MK5B and MT13B glass ceramics is 
described using in vitro and in vivo testing. The in vitro biological activity of the glass 
ceramics was evaluated by using MG63 osteoblast-like and human bone marrow 
osteoblastic cells. Cell morphology, proliferation and differentiation and the ability to form 
a mineralized extracellular matrix onto the materials surface were assessed. The in vivo 
biodegradation and tissue response induced by the presence of MK5B and MT13B glass 
ceramics were also shown in this chapter. The in vivo studies were followed over a period 
of 12 weeks using a rabbit model. A mixed granulometry ranging from 250-355 µm and 
355-425 µm with a ratio of 1/1 was implanted in the tibiae of the rabbits and the tissue 
reaction at the implantation site as well as the biodegradation were evaluated as function of 
the implantation time. 
 
The last chapter 4 of this thesis presents general conclusions of the performed research, 
outlining the most important aspects. 
 
The author did all of the experimental work described in this thesis, except the preparation 







Literature overview  
 
1. General outline 
Human beings are undeniably the most complex organism on this planet. The human body 
is a single structure but it is composed of billions of smaller structures, with the four major 
ones being cells, tissues, organs and systems(1,2). 
The average life expectancy has been increasing progressively through time. Nevertheless, 
some difficulties arise as a result of a longer lifespan. The quality of life often deteriorates 
between 60 and 90 years due to the gradual degradation of our connective tissue (skeletal 
system). The need to repair or replace the deteriorated skeletal system has led to the 
development of bone graft substitutes(3,4). Over the years, the use of these substitutes 
became standard. The range of applications continues to grow as medical research keeps 
exploring new scientific frontiers for diagnosing, treating, curing and preventing bone 
diseases. This continuous knowledge is needed to develop innovative methods, new 
materials as well as adjustment of existing bone grafts. At present, the design of proactive 
materials is highlighted. These materials elicit specific, desired, and timely responses from 
surrounding cells and tissues. To do this, they are either designed with structures similar to 
living tissues or are combined with specific molecules to promote rapid and total healing(5-
7). Undoubtedly, bone grafts substitutes have had a major impact on the practice of modern 
medicine and patient care in both saving and improving the quality of human life. 
Chapter 1 
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2. Bone tissue 
Bone is a living, growing specialized form of connective tissue. As a part of the human 
skeleton, bone tissue provides a rigid framework that support and protects the internal 
organs(1,8-12). 
Bone tissue is essentially constituted of an extracellular matrix and three main cell types. 
The extracellular matrix is a composite of inorganic (contains ≅ 65%) and organic 
(contains ≅ 35 %) phases. The components of the inorganic part are calcium-containing 
minerals, and it is the mineral content that accounts for the rigidity and strength of the bone 
tissue while still maintaining some degree of elasticity.  The organic part of the 
extracellular matrix is basically composed of collagen type I and numerous non-
collagenous proteins. This organic matrix is calcified by the deposition of crystals of the 
mineral phase, which is a highly substituted hydroxyapatite(8,9,11,12).  
The three main cell types involved in the development, growth and remodelling of bone 
are osteoblasts, osteocytes, and osteoclasts(9,10,12-15). The osteoblasts are fully differentiated 
cells responsible for the production of the extracellular bone matrix and its mineralization. 
It originates from less differentiated precursor cells known as osteoprogenitor or 
mesenchymal stem cells. These are usually found in the growing portions of bones, 
including the periosteum(10,12,13,16,17).  
The osteocytes are the most abundant cell type in bone. They are responsible for bone 
matrix maintenance by secreting enzymes and maintaining its mineral content. Osteocytes 
derive from osteoblasts and they are not on the bone surface but regularly entrapped 
throughout the extracellular matrix(10,12,17-20). 
Osteoclasts are giant multinucleated cells responsible for bone resorption. They originate 
from haematopoietic stem cells and are usually found upon bone surfaces which are 
undergoing bone resorption(10,13,21-24).  
 
Bone development continues throughout adulthood in a constant remodelling process, 
involving the equilibrium between the resorption of bone by the osteoclasts, as well as the 
formation of new bone by the osteoblasts(9,13-15,17,25,26). During the bone remodelling 
process, osteoclasts (bone resorption cells) remove old bone tissues by resorption, whereas 
osteoblasts (bone forming cells) work to refill the resorption cavities with new bone tissue. 
Literature overview 
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These two processes are tied together and are responsible for the renewal of the skeleton, 
necessary for the maintenance of bone tissue integrity and mineral homeostasis(10-14). 
The first bone formed during bone development or in the repair of fracture healing, 
tumours and some metabolic diseases is an immature and primitive bone called woven 
bone. The immature bone is gradually replaced by organised mature bone, lamellar bone. 
This kind of structure constitutes most of the mature skeleton. At the macrostructure level, 
lamellar bone is distinguished into cortical (or compact) and cancellous (or trabecular) 
bone(10,13,17,25,27). They differ by the spatial orientation of its elements, organic and mineral, 
and by its characteristic locations in the skeleton. Compact bone represents nearly 80% of 
the skeleton mass, and comprises the outer parts of bones; it consists of a thick, hard and 
dense layer of calcified tissue. Trabecular bone only represents 20% of the skeletal mass, 
and fills the inner space of bones that consists of a network of thin calcified trabeculae. 
This bone occurs near the end of long bones and between the surfaces of flat 
bones(9,12,13,27).  
Bone executes several functions, which can be categorised as mechanical, metabolic and 
protective(11-13,27). Mechanically it acts as support and a site of muscle attachment for 
locomotion. Metabolically, bone acts as a reserve of ions for the entire organism, 
especially calcium and phosphate, and protectively it shields vital organs and bone 
marrow. The mechanical and protective functions are mainly performed by cortical bone 
and the metabolic functions are supported by trabecular bone.  
 
3. Bone grafts 
Bone graft is the term commonly used to refer to a wide range of materials used in surgical 
methods to stimulate new bone formation.  It provides a framework through which the host 
bone can regenerate and heal(3,28,29). Many medical situations call for the use of bone grafts. 
Among them are gaps in bone caused by trauma, facture or disease as well as abnormal 
skeletal development(3,30). The types of bone grafts available to treat such problems 
essentially includes autografts, banked allografts and xenografts as well as a wide range of 
synthetic materials (alloplastics) such as ceramics, polymers and composites(3,29). 
For many years the autograft has been considered as the gold standard for bone repair and 
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regeneration. It is defined as tissue transplanted from one site (donor site) to another 
(recipient site) within the same patient(28-30). It is immunologically safe, thus limiting 
rejection concerns. These grafts provide all three requirements for the best bone 
regeneration: scaffold for osteoconduction, growth factors for osteoinduction and 
progenitor cells for osteogenesis(3,4,28). The use of autogenous bone grafting, however is 
associated with various uncontrollable factors. The harvest of the autograft implies an extra 
and invasive surgical procedure and therefore post-operative continuous pain at the donor 
site or even donor site morbidity may occur. Wound infection, haematoma and 
hypersensitivity are other possible difficulties associated with autologous bone grafting. 
Another disadvantage is the limited amount of bone available for harvesting. The common 
donor site is the iliac crest, although bone from the tibia, fibula, distal end of the radius and 
posterior portions of the spine can also be used(4,30-32). 
 The allograft is defined as a tissue graft between individuals of the same species but with 
different genetic composition. The use of this graft type can solve some of the drawbacks 
related with autologous bone grafting since the second surgical procedure is eliminated and 
the quantity of tissue is available in large amounts(31,33,34). Nevertheless, this alternative is 
associated with some problems including the risk of disease transmission(4) to the recipient 
and immunogenicity(35). To lessen the potential risks to the recipient, allografts are 
intensively treated prior to preservation for storage, using the processes of freeze-drying, 
irradiation and demineralisation. However, these processes contribute to increased costs 
and diminished mechanical and biologic properties while the possibility of disease 
transmission still remains(4,31,34,36). 
The xenograft (xenogenic bone graft) is defined as a tissue graft from a donor of a different 
species than the recipient. This kind of graft material allows the extraction of larger 
amounts of bone with a specific microstructure, reduces morbidity by eliminating the 
donor site and can be used as bone graft expanders by mixing them with autogenous 
bone(29,34). Xenografts can be derived from mammalian bones and coral exoskeletons. 
Bovine derived bone has been commonly used(37,38), even though other sources such as 
porcine or murine bone are available. Xenogeneic bone was popular in the 1960’s but fell 
into disfavour due to reports of patients developing autoimmune diseases following bovine 
bone transplants(39,40). The re-introduction of these products in the 1990’s arose after the 
development of methods to deproteinate bone particles, which reduces the antigenicity 
making these implants more tolerable to host tissues(36). However, the use of bovine 
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xenograft is still a concern due to the possibility of future bovine spongiform 
encephalopathy from potentially slow virus transmission in bovine-derived products.    
 
Despite the benefits of bone-derived grafts, their limitations have driven the search for 
synthetic alternatives(4,31,32,41-43). Many researches have attempted to develop synthetic 
bone graft to provide an alternative to bone-derived grafts based on three basic criteria for 
successful grafting(3,4,29,42): 
 
(1) Osteoconduction to provide a structural framework and environment that 
supports the migration, attachment and growth of osteoblasts and 
osteoprogenitor cells into the graft 
(2) Osteoinduction to recruit and stimulate osteoprogenitor stem cells or non-
differentiated stem cells to differentiate into osseous forming cells 
(3) Osteogenesis to provide bone formation by transplanted living cells 
 
Depending on the purpose of the bone graft, one or more of the above described properties 
may be more desirable than others. Besides providing these characteristics, the bone grafts 
should be easy to use clinically and cost-effective. 
Nowadays, many of the bone grafts under clinical evaluation use synthetic materials as an 
alternative to the bone-derived grafts, for instance: synthetic ceramics, polymers and 
composites(4,32,41,42). However, none of the above mentioned possess osteogenic properties 
and normally they also lack intrinsic osteoinductivity(31,32,41,42,44). The awareness of these 
failings has driven the conception of new strategies. The two main strategies that have 
emerged are the stimulation of bone formation using osteoinductive bone substances and 
the creation of biomaterials composed of an osteoconductive scaffold and osteogenic 
tissue. In the first strategy the osteoinductive bone substances mostly used are bone 
morphogenetic proteins (BMP), transforming growth factors  (TGFs ), insuline growth 
factors (IGFs), platelet derived growth factors (PDGF´s), fibroblast growth factors (FGFs) 
and vascular endothelial growth factors (VEGFs)(4,45-47). The second strategy lies in the 
construction of a bone graft substitute combining the osteoconductive scaffold with 
osteogenic cells of the patient. In addition to the osteoconductive scaffold providing a 
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scaffold for the formation of new bone, it will function as a carrier for the cells as well as a 
dynamic delivery system for osteoinductive bone substances. Combining these concepts, 
namely an osteoconductive scaffold with osteoinductive growth factors and osteogenic 
cells may even exceed the current requirements of bone-derived grafts(7,48-53).  
 
3.1. Synthetic bone graft substitutes (alloplastics)
Synthetic bone graft substitutes offer many advantages over applications using bone-
derived grafts, including unlimited supply, purity of the material and absence of 
disease(32,54). The wide variety of compositions allows the surgeons to choose a specific 
combination of strength, elasticity and durability for a given procedure and therefore to 
simplify the operative practice(4,54).  
There are two main categories of synthetic bone graft substitutes: ceramic- and polymer-
based. Each class has a distinct profile of properties in terms of strength, flexibility and 
ability for tissue ingrowth that influences the decision of which material should be used for 
each specific purpose.  
The ceramic-based class includes calcium phosphates, calcium sulphates, bioactive 
glasses, either alone or mixed with other materials(29,55,56). The polymer-based class 
comprises degradable polymers used alone or in combination with other 
materials(29,54,55,57). Biodegradable polymers are used in a variety of surgical applications, 
and more recently the use of bioresorbable polymers has expanded to include scaffolds for 
tissue engineering in various geometric forms including porous membranes, porous blocks 
and microspheres. Most of the biodegradable polymers in use in tissue engineering at 
present belong to the polyhydroxyl acid family, namely polyglycolic acid (PGA) and 
polylactic acid (PLA) or copolymers of both(58,59). When these materials are used as bone 
grafts, either alone or as a composite, they are designed to form osteoconductive surfaces. 
 
3.1.1. Ceramic-based bone grafts substitutes 
Ceramics are materials composed of metallic and non-metallic elements held jointly by 
ionic and/or covalent bonds(55,56). The use of ceramics as bone graft substitutes, particularly 
calcium phosphates, is motivated because they are the main inorganic constituent of hard 
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tissues in the body(2,56,60). Additionally, calcium phosphates are osteoconductive, which is 
one of the characteristics required in a bone graft. They are generally used in dense, 
granular or porous form as well as coatings of metal prosthesis and implants, or as a 
component of a composite.  
The success of using ceramics as bone graft substitutes depends upon the interaction 
between the implant and host tissue. When implanted in living tissues, all materials elicit a 
response from the host and generally both tissue and material undergo physical and/or 
chemical modifications. Based on these modifications, ceramics can be classified as(43,56,61-
67): 
 
(1) Nearly inert ceramics 
(2) Surface reactive ceramics (bioactive) 
(3)  Bioresorbable ceramics 
 
The nearly inert ceramics such as alumina and carbons are chemically stable and elicit 
minimal response with surrounding tissue, maintaining its characteristics throughout the 
entire period of implantation in the organism(55,62,64).  
The surface reactive ceramics are midway between nearly inert and resorbable in 
behaviour. This kind of ceramic elicits a biological response to facilitate a direct chemical 
bond between the material surface and the surrounding tissues. Some of the materials 
included in this group are bioactive glasses (Bioglass®), glass-ceramics (Ceravital, 
Cerabone A/W) and hydroxyapatite [HA; Ca10(PO4)6(OH)2](55,62,68-71). 
Bioresorbable ceramics are designed to degrade progressively with time and be replaced 
with natural host tissue, without toxicity and rejection. This biodegradation may be caused 
by three factors(55,65,72,73): 
 
(1) Physicochemical dissolution, which depends on the solubility product of the 
material and the local pH of its environment 
(2) Physical disintegration into small particles as a result of preferential 
chemical attack of grain boundaries 
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(3) Biological factors, such as phagocytosis 
 
Bioresorbable materials may show some complications in the clinical use, such as:  
 
(1) Maintenance of strength and stability of the interface during biodegradation 
and replacement by the natural host tissue 
(2) Matching resorption rates to the repair rates of body tissues. This point is 
very important, since some materials dissolve too quickly and some too 
slowly 
 
Since a great concentration of ions or/and particles of a bioresorbable material is released, 
it is important that it consists only of metabolically tolerable substances, which restricts its 
compositional design and therefore the mechanical behaviour and eventually its final 
applications. 
 
3.1.1.1. Synthetic hydroxyapatite-based materials 
Hydroxyapatite (HA) is one of the most biocompatible materials and has been used as a 
bone graft for a long time. The synthetic hydroxyapatite materials resemble the mineral 
part of bone, but they present some differences such as ion substitutions that alter the 
interaction between the mineral and organic phases of bone, and ultimately the properties 
of bone. For that reason, some ions have been intentionally added to the hydroxyapatite 
structure. These ions include carbonate ions substituting both hydroxyl and phosphate 
groups, fluoride ions substituting hydroxyl groups, silicate ions substituting phosphate 
groups, as well as magnesium ions substituting calcium(55,61,74-79). 
An ideal bone graft ought to present an adequate resorption rate to be substituted as new 
bone is synthesised and remodelled. Most hydroxyapatite implant materials are 
osteoconductive, however they resorb very slowly. Therefore, different approaches have 
been used in order to overcome this disadvantage. For example, hydroxyapatite can be 




3.1.1.2. Synthetic tricalcium phosphate-based materials  
Tricalcium phosphate [TCP; Ca3(PO4)2] has four polymorphs, , ,  and super (55). The 
most clinically used polymorph is β-TCP. The α-polymorph is more reactive in aqueous 
solutions than the β-polymorph, therefore more soluble(55,83). Besides its profile of 
biocompatibility and osteoconductive ability, TCP has a higher solubility and resorption 
rate than hydroxyapatite ceramics(78,84,85). Due to their relative solubility TCP is generally 
used in circumstances where structural support is less important. 
 
3.1.1.3. Glass-based materials 
Glass-based materials are considered surface reactive ceramics(86,87). When implanted, the 
materials undergo dissolution and release ions into the surrounding environment with 
consequent local pH changes. The composition of the materials controls their surface 
reactivity. These kind of materials do not become encapsulated when implanted, but 
closely adhere to the surrounding living bone tissues(88,89). 
Almost all of the bioactive glasses and glass ceramics used contain large amounts of SiO2. 
Two of the most well known implants are Bioglass® and Ceravital®(71,90-92). Nevertheless, it 
is common knowledge that silica-free calcium phosphate glass-based materials also have 
high potential for being used as bone graft substitutes. 
 
3.1.2. Medical applications 
The research on the bone graft field started to focus on the development of synthetic 
substitutes for particular applications, such as craniofacial, oral/maxillofacial and 
orthopaedic surgery(4,7,27,29,30,93). Table 1 shows a list of some of the most used 
commercially available ceramic-based grafts. These substitutes are available in different 
forms such as blocks, granules, cements and gels. The block and granule types are the most 
commercialized on the market. Blocks are normally used in situations of trauma, interbody 
spinal fusion, and non-unions. Granules are generally used for posterior/lateral spinal 
fusion, filling cystic voids, as well as for hip and knee revisions. One of the factors 
influencing the physician’s choice of bone graft is the cost-effectiveness. Granules have a 
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significant price advantage over the other forms of bone grafts(27,29). 
 








Ceros 80 Dense polycrystalline HA Straumann Ltd, UK 
Biocoral Natural mineral skeletons of 
scleractinian corals 
Inoteb, France 
Pro Osteon Coralline macroporous HA Interpore Int., USA 
Osteograft Crystalline HA CeraMed, USA 
Calcitite Dense crystalline HA Calcitek, USA 
Tricalcium phosphate 
Chronos/Ceros 82 Tricalcium phosphate Mathys, Suisse 
Biosorb Tricalcium phosphate SBM S.A, Lourdes 
Vitoss Ultraporous TCP Orthovita, USA 
Cerasorb Tricalcium phosphate Curasan AG, Germany 
Bioactive glasses 
Bioglass Bioactive glass: 45% SiO2, 24% CaO, 
24.5% Na2O, 6% P2O5, mol% 
Novabone, USA 
Ceravital Group of glasses and glass ceramics of 
various compositions 
E.Pfeil & H.Brömer, 
Germany 





The nature of glass and the glass transition mechanism is probably the deepest and most 
interesting unsolved problem in solid state theory. Glasses have found to share two 
distinguishing characteristics: (1) time-dependent glass transformation behaviour and (2) 
no long range atomic order. Based in these features, a glass can be defined as “an 
amorphous solid completely lacking in long range, periodic atomic structure and 
exhibiting a region of glass transformation behaviour (96-100). 
 
Traditionally glass transformation behaviour is discussed on the basis of either enthalpy or 
volume versus temperature diagrams, such as that shown in Figure 1. 
 
 
Figure 1 – Changes associated with heating and cooling in systems liable to glass formation. 
 
 
Depending on the cooling rate, when a liquid is cooled to below its melting temperature 
(Tm), it can either form a crystalline state or a super-cooled liquid (Figure 1). The transition 
from a super-cooled liquid to a solid glass is known as the glass transformation region and 


























temperature at which glass transition occurs is dependent on cooling rate, when a slow rate 
is used the structural units have more time to reorganize and therefore Tg is lower. On the 
other hand, if a rapid cooling rate is used the transition into a glass occurs at a higher 
temperature, owing to the lower time available for the molecular structural arrangement.  
 
4.1. Principles of glass formation 
Among the several theories initially proposed for glass formation, the statements by 
Zachariasen have become the basis for the models for glass structures termed the random 
network theory. Zachariasen noted the following characteristics in glass forming oxides: 
(1) the material contains a high proportion of cations which are surrounded by either 
oxygen triangles or oxygen tetrahedral, (2) these polyhedra are connected only by their 
corners, and (3) some oxygen atoms are linked to only two such cations and do not form 
additional bonds with other cations(97,99,105-108). 
Complementary studies that were performed to explain glass formation classify oxides into 
three groups: network forming oxides, intermediate oxides and network modifying oxides. 
Intermediate oxides are those oxides that do not form glasses by themselves, however they 
are incorporated into the network of the glass formers(97,99,106,108). Network modifying 
oxides can also take part in glass formation by acting to modify the glass network, 
therefore modifying the glass properties. These oxides do not form networks although they 
occupy interstitial sites in the structure of a glass network. They are essentially the alkali or 
alkaline earth metal oxides. The addition of these oxides to the glass network results in its 
weakness due to the formation of non-bridging oxygens within the glass, i.e. disrupt the 
network continuity. Examples of such network modifiers are: Na2O, K2O, Li2O, CaO and 
MgO.  
Recent theories of glass formation not only address the question of why one specific 
material will form a glass, but also form a glass processing approach. The new approach to 
glass formation, known as the kinetics theory of glass formation, has largely replaced the 
earlier structural theories. Virtually any material will form a glass if cooled so rapidly that 
insufficient time is provided to allow the reorganization of the structure into the periodic 




4.1.1. Structure of phosphate glasses 
Phosphate glasses consist of a polymer-like, regular tetrahedral structure based on [PO4] 
groups, with their structure generally described using Qn terminology, where n represents 
the number of bridging oxygen atoms per [PO4] tetrahedron. The networks of phosphate 
glasses can be classified according to the ratio of oxygen to phosphorus ions [O]/[P], 
which establishes the connections between the P-tetrahedra through bridging oxygens(99,113-
116). The most polymerized glass forms a cross-linked Q3 network (ordered structure), with 
each tetrahedron connected to three others. The introduction of components to the glass 
network, such as modifier oxides, reduces the polymerization between the tetrahedra due to 
the creation of non-bridging oxygens in the phosphate network. This depolymerization 
weakens the glass structure and consequently changes the final properties of the glass(99,113-
115,117). The resulting depolymerization of the glass network with the addition of an alkali 
oxide (R2O) can be described by the following reaction, illustrated schematically in Figure 
2: 
2 Qn + R2O  2 Qn-1 
 
Considering the addition of modifier oxides to the glass structure and consequently 
increasing the [O]/[P] ratio, glasses with different structures can be obtained(113,115), (Table 
2): 
 
(1) Glasses with ratios in the region of 2.5 and 3.0 are known as branched 
ultraphosphates (Q3 and Q2). Q3 structures have three bridging and one non-
bridging oxygens per phosphate tetrahedron 
 
(2) When the ratio is equal to 3, the metaphosphates (Q2) are formed. Their 
structure becomes a collection of tetrahedral chains and rings. Technically, the 
glasses formed in the region between 3.0 and 3.5 are designated as long-chained 
polyphosphates, however generally they are also referred to as metaphosphates. 
Their structures are comprised of chains of tetrahedra linked at two corners 
terminated at each end by a tetrahedra sharing only one corner (Q2 chains 
terminated by Q1 tetrahedra). Q2 structures have two bridging and two non-
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bridging oxygens per phosphate tetrahedron 
 
 
Figure 2 – Effect of [O]/[P] ratio on phosphate network structures 
 
(3) Increasing the ratio to 3.5 will result in a pyrophosphate structure (Q1), where 
the tetrahedra are only linked at one corner. Q1 structures have one bridging and 
three non-bridging oxygens per phosphate tetrahedron 
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the tetrahedra isolated, and this structure is designated as orthophosphate (Q0). 
Q0 structures have no bridging and four non-bridging oxygens per phosphate 
tetrahedron 
 
Phosphate glasses can be prepared with a wide variety of modifiers and additives, allowing 
the properties of the final glass to be tailored for specific applications. 
 
Table 2 – Glasses with different structures based on the [O]/[P] ratio.  
Regions xR2O (or R’O) (1-x) P2O5 glasses [O]/[P] ratio Qn groups 
Ultraphosphate 0  x <0.5 2.5 < [O]/[P] <3.0 Q2 and Q3 
Metaphosphate x = 0.5 [O]/[P] =3.0 Q2 
 0.5 < x <0.67 3.0< [O]/[P] <3.5 Q1 and Q2 
Pyrophosphate    x = 0.67 [O]/[P] = 3.5 Q1 
 0.67< x <0.75 3.5< [O]/[P] <4.0 Q1 and Q0 
Orthophosphate x = 0.75 [O]/[P] = 4.0 Q0 
 
5. Glass ceramics 
Glass ceramics are polycrystalline materials composed of one or more glassy and 
crystalline phases. They are usually obtained by forming a base glass, most commonly by 
the conventional technique of melting, which is next heat treated at an adequate 
temperature cycle to be converted into a glass ceramic material. The control of heat 
treatment cycle in the preparation of glass ceramics is of extreme importance in order to 
achieve a final microstructure with desirable properties(118-125).  
Particular additives may be incorporated into the base glass composition to induce the 
nucleation of phases with specific physico-chemical properties in the glass ceramic 
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formation. More specifically, it allows the preparation of glass ceramic materials with the 
presence of biocompatible and bioresorbable phases. The characteristics of the final 
constituent phases and microstructure of the glass ceramic establish its properties and main 
applications. There are three main techniques used for the preparation of glass ceramic 
materials(120,126): 
 
(1) Casting and controlled crystallization 
(2) Sintering and crystallization of glass powder 
(3) Sol-gel 
 
The later sol-gel technique will not be reviewed in this description.   
 
5.1. Casting and controlled crystallization method
Controlled crystallization is a fundamental process in the preparation of glass ceramic 
materials. It is based on the preparation of glass by the conventional technique of melting 
and casting. The glass is first melted and then cast into a block. Afterwards, it is annealed 
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The heat treatment used to attain a glass ceramic material involves two mechanisms: 
nucleation and crystal growth(108,120,127-131). 
Nucleation is the key process in controlling crystallization, since it is the initial step of a 
phase transformation. Since the phase transformation does not occur spontaneously 
throughout the base glass, the presence of a nucleus it needed on which the crystal 
subsequently grows. If the formation of nuclei does not happen, crystal growth can not 
occur and therefore the crystallization is avoided(120,122,132). This process can either occur 
via homogeneous nucleation or heterogeneous nucleation. 
In homogeneous nucleation the initial stage occurs spontaneously within the melt with no 
preferential sites for nucleus formation, i.e. occurs randomly in space and time. The 
composition of the melt and crystal are the same(120,132-134).  
The heterogeneous nucleation involves formation of the nuclei of a new phase on the 
surface of a pre-existing surface, such as foreign surfaces, grain boundaries, impurities, 
crucible wall, bubbles, i.e. occurs from specific sites in the sample (120,132,135). 
In this kind of nucleation a component designated as nucleating agent can be added in 
small percentages into the base glass facilitating the nucleation process. They act as a 
catalyst in the glassy matrix, as they reduce the energy barrier for nucleation(99,122,136,137). 
The ability of tailoring the glass ceramic microstructure by using various additives allows 
an excellent control of the properties of the final material. 
The heat treatment used in the preparation of glass ceramics, which interferes with the 
nucleation and the growth stages, can lead to two situations: uncontrollable and 
controllable crystallization(122):  
 
(1) If the nucleation and growth curves overlap in a certain temperature range T2-T3 
(Figure 4a), the control of the crystallization process is limited or even 
impossible. This phenomenon takes place when nucleation and crystal growth 
occur simultaneously in a single-step heat treatment (Figure 5a) 
 
(2) On the other hand, if the overlap of two processes is minimized, nucleation and 
growth curves are separated and a controllable crystallization is achieved 
(Figure 4b). The glass is heated to the nucleation temperature, between T1 and 
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T2, to allow nuclei formation. After a certain period of time, the temperature is 
increased to the range of T3 and T4 for crystal growth. Following this, the 
sample is then again cooled to room temperature. This two-step heat treatment 
is used to prepare glass ceramics in a controlled way (Figure 5b). 
 
Figure 4 – Nucleation and crystal growth temperatures. (a) uncontrollable and 









Figure 5 - Single-step heat treatment (a) and two-step heat treatment (b). 
 
5.1.1. Bulk and surface crystallization
The crystallization process can occur within bulk glass or on its surface, referred to as bulk 
































If crystallization occurs from nuclei dispersed throughout the bulk of the base glass, then it 
is termed bulk crystallization. Both homogeneous and heterogeneous nucleation may occur 
during bulk crystallization (Figure 6).  
If the crystallization process is initiated on the surface of the glass sample through 
heterogeneous nucleation, it is called surface crystallization. The crystals grow from the 




Figure 6 – Bulk and surface crystallization. 
 
5.2. Sintering and crystallization by glass powder method
Glass sintering with subsequent heat treatment of crystallization (powder technology route) 
is also a useful method in the preparation of glass ceramic materials. Compared with the 
well-known conventional process, this method allows the preparation of complex shapes as 
well as glass ceramic composite materials. This procedure is based on the preparation of a 
base glass that is first melted and then quenched as a frit. Subsequently, the frit is crushed 
and milled to obtain a glass powder with a small range of particle size. Afterwards, the 
glass powder is compacted at room temperature to shape the final material and then 
subjected to an adequate heat treatment for sintering and crystallization (Figure 7). These 































































simultaneously as one stage. Depending on the order of events of the powder sintering 
process, glass ceramic materials with different properties can be obtained. If the sintering 
stage ends before crystallization begins, extremely dense and low porosity materials are 
obtained. On the other hand, if the crystallization stage occurs before or simultaneously 
with the sintering one, porous and heterogeneous materials are obtained(139-141). 
 
 
Figure 7 – Procedure for the preparation of a glass ceramic by the powder technology 
route (a) and a sequence for the densification process (b). 
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This section describes the physicochemical characterization of calcium phosphate glass 
ceramics which is presented as follows: 
2.1. In vitro degradation studies of calcium phosphate glass ceramics prepared by 
controlled crystallization  Journal of Non-Crystalline Solids 330 (2003) 81-89. 
2.2. Crystallization studies of biodegradable CaO-P2O5 glass with MgO and TiO2 for bone 
regeneration applications  Glass Technology 45 (2004) 78-79. 
2.3. In situ thermal and structural characterization of glass ceramics containing TiO2 and 
MgO oxides  Journal of Non-Crystalline Solids 351 (2005) 810-817. 
2.4. Physicochemical degradation studies of calcium phosphate glass ceramic containing 
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ABSTRACT 
Calcium phosphate glass ceramics with incorporation of small additions of two oxides, 
MgO and K2O were prepared in the metaphosphate and pyrophosphate region, using an 
appropriate two-step heat treatment of controlled crystallization defined by differential 
thermal analysis results. Identification and quantification of crystalline phases precipitated 
from the calcium phosphate glass were performed using X-ray diffraction and Rietveld 
analysis. The β-Ca2P2O7 (β-DCP), KCa(PO3)3, β-Ca(PO3)2 and Ca4P6O19  phases were 
detected in the glass ceramics. In order to evaluate the degradation of the glass ceramics 
prepared, degradation studies were carried out during 42 days in Tris – HCl solution at 
37ºC, pH 7.4, using granules in the range of 355 – 415 µm. The materials presented a 
weight loss ranging up to 12%. The ions leached during the immersion mainly originated 
from the KCa(PO3)3 phase, probably due to the presence of K+ ion in the calcium 
metaphosphate, and the residual glassy phase. The structural changes at the surface of 
materials during degradation have been analyzed by Fourier transform infrared 
spectroscopy and X-ray diffraction. Results showed that significant surface changes 
occurred with immersion time, with the decrease of KCa(PO3)3, β-Ca2P2O7 and β-
Ca(PO3)2 phases occurring at different periods of immersion. This study has demonstrated 
an easy way to prepared calcium phosphate materials with specific calcium phosphate 








The capacity of the human body to regenerate bone components that are lost, damaged or 
diseased is limited in several situations, so synthetic materials to fill bone defects have 
been developed(1,2). Calcium phosphate materials have some outstanding properties, 
namely similarity in composition to bone mineral and osteoconductivity(3-5). Products in 
the bone graft market based on hydroxyapatite and tricalcium phosphate have been used 
clinically. However, the success of these materials is limited mainly due to low toughness, 
low elasticity, low ability to be resorbable and lack of osteogenic properties(6). To 
overcome the low mechanical properties several silicate glasses and glass ceramics have 
been developed and products such as Bioglass®, Bioverit® and Ceravital® have been 
available commercially for a long time. Nevertheless, all these materials still show a lack 
of both osteogenic properties and complete biodegradability after implantation. 
Bioresorbable glass ceramics containing large amounts of biodegradable calcium 
phosphate crystals are believed to be one of the best approaches to obtain materials of great 
interest for bony defects associated with or without the release of biological therapeutic 
molecules(7,8). 
Phosphate glasses consist of a polymer-like, regular tetrahedral structure based on [PO4] 
groups, with their structure generally described using Qn terminology, where n represents 
the number of bridging oxygens per tetrahedron(9,10). Depending on the [O]/[P] ratio as set 
by glass composition, the phosphate glasses can be made with a series of structures: (a) 
cross-linked network of Q3 tetrahedra (vitreous P2O5), (b) polymer-like metaphosphate 
chains of Q2 tetrahedra, (c) “invert” glasses based on small pyro- (Q1) and orthophosphate 
(Q0) anions. The addition of a modifier oxide leads to the creation of non-bridging oxygens 
in the glass that result in a depolymerization of the phosphate network, with oxygen atoms 
breaking the P-O-P links. This breakage in the structure of phosphate glass weakens and 
reduces their durability(10-12).  
Phosphate-based glasses seem to be used as bioresorbable materials because of their 
solubility behaviour(13,14), since their solubility may be controlled by altering their chemical 
composition(15). Some studies have reported that using appropriate heat-treatment the 
microstructure can be controlled by controlling the phases and sizes of crystals that are 
precipitated in the glasses(16,17). 
The aim of this work was to develop glass ceramics from the system CaO-P2O5-MgO-K2O 
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with compositions located mainly between the metaphosphate (Q2) and the pyrophosphate 
(Q1) region (3.0 < O/P < 3.5). A two-step heat treatment, defined by differential thermal 
analysis (DTA), was used to achieve nucleation and crystal growth in a controlled manner. 
In vitro acellular degradation studies were performed to assess their resorbability potential 
according to standard ISO 10993-14.  
 
MATERIALS AND METHODS 
Preparation of glass samples 
A phosphate glass (MK5) was prepared with a composition of 45CaO-45P2O5-5K2O-
5MgO (mol %), using the following analytical chemicals: CaCO3, MgHPO4.3H2O, K2CO3 
and H3PO4 (85%). The glass was obtained by melting in a platinum crucible at 1450ºC for 
1h. The melt was quickly poured into a steel mould preheated at 370ºC, and then annealed 
for 30 min at 25ºC above the glass transition temperature, as determined by DTA analysis. 
 
Preparation of glass ceramic samples 
Differential thermal analysis (DTA) of the amorphous glass was performed to determine 
the exothermic and endothermic heat changes such as the glass transition temperature (Tg), 
crystallization temperature (Tc) and melting temperature (Tm). The analyses were carried 
out in a DTA-50 (Shimadzu) using an inert nitrogen atmosphere, a heating rate of 
15ºC/min and a temperature scanning up to 1200ºC. Alumina (Al2O3) was used as a 
reference. Volume crystallization was achieved through an efficient two-step heat 
treatment, as previously reported by Zhang and Santos(8), and results are shown in Fig. 1.  
Three different heat treatments were performed leading to MK5B, MK5C and MK5E glass 




The density of the glass and glass ceramics was determined using Archimedes principle 
with water as the immersion liquid. All measurements were performed in triplicate. 







spectroscopy (VOYAGER, Noran Instruments) was used to characterize the 
microstructures of studied materials before and after the heat-treatment. The precipitated 
phases were examined at a magnification of 4000× using an accelerating voltage of +15 









Figure 1 - DTA curve of the calcium phosphate glass MK5. Points B, C and E correspond to three 
different temperatures used in the heat treatments to obtain crystallization: 690, 739 and 756ºC. Tg, 
Tc and Tm stand for glass transition, crystallization temperature and melting temperature,  
respectively. 
 
Table 1 - Temperatures used in the heat treatment cycle applied to  




            
     a Nucleation temperature 
     b Crystal growth temperature. 
 
X-ray diffraction (XRD) and Rietveld analysis were used to identify and quantify the 
crystalline phases that precipitated from the mother glass. For X-ray diffraction 
measurements, samples were ground to a fine powder and analyzed using a Siemens D 
5000 diffractometer, using flat plate geometry and Cu Kα radiation. Data were collected 
using a scintillation counter and a graphite diffracted beam monochromator, from 10 to 70º 
(2θ), with a step size of 0.02º and a counting time of 5 s per step. Quantitative phase 































(GSAS, Los Alamos National Laboratory). The weight fraction of each crystalline phase is 
calculated from an equation that accounts for the scale factor of each phase and the number 
of formula units, the mass of formula units and the cell volume of each phase(18). 
The samples used in the degradation testing were ground to a small particle size in order to 
be analyzed by Fourier transform infrared spectroscopy (transmission mode) using a 
system 2000 FTIR spectrometer (Perkin Elmer). The resolution used was 4 cm-1 and the 
number of scans was not less than 100. 
 
Degradation testing 
The degradation testing was performed according to ISO 10993-14 - “Biological 
evaluation of medical devices- Part 14: Identification and quantification of degradation 
products from ceramics”. Granules with a size between 355 and 415µm were used as 
obtained by automated controlled sieving technique. Tests were carried out in 
Tris[hydroxymethyl]aminomethane-HCl (Tris-HCl) solution (pH 7.4) at 37ºC, with a 
mixing speed of 120 rpm, using triplicate samples. At the end of each period of immersion 
time (0.5, 3, 7, 14, 28 and 42 days), granules were separated from solution by filtration 
(0.2µm), washed in deionised water and dried to constant weight. A relative weight loss 
percentage of samples was calculated from the following equation:  
 
Weight loss (%) = [(W0-Wt)/W0]× 100 
 
where W0 and Wt stand for initial weight and weight after a specific immersion time, 
respectively. 
The concentration of calcium, magnesium and potassium ions in the soaking solution was 
measured by flame atomic absorption spectroscopy (AAS) (Unicam, Model Solar). The 
phosphorus concentration was measured from total phosphate groups by ultraviolet 
spectroscopy using the molybdenum blue method (Philips, Model PU 8620, UV-Vis Nir). 
The pH value at the end of each immersion time was measured at 37 ± 0.1ºC. 
 
RESULTS 







Figure 1. Two exothermic peaks can be observed due to crystallisation phenomena at onset 
temperatures of 627 and 739ºC, and two endothermic peaks at onset temperatures of 773 
and 896ºC correspond to melting. The latter two peaks are suggested to be due to the 
partial melting of crystalline phases or residual glass matrix. The temperature of glass 
transition at mid point (Tg) was 534ºC. 
Figure 2 shows the XRD patterns of glass samples after the three different heat treatments 
(nucleation and crystal growth) used. The patterns are almost the same for all three heat 











Figure 2 - XRD patterns of the three glass ceramics prepared, MK5B, MK5C and MK5E. 
 
Table 2 shows the percentage of each precipitated phase in the crystallized materials 
obtained by applying the Rietveld analysis to XRD patterns. The predominant phase in all 
samples prior to soaking was β-Ca2P2O7, with the other phases ranging in content from 0 to 
20%. The sample MK5B appeared to have negligible Ca4P6O19 but contained significantly 
more β-Ca(PO3)2 than MK5C or MK5E. All samples appeared to have a comparable 
content of amorphous glassy phase, as indicated by a broad amorphous band in the 
diffraction pattern. Comparing the area under the amorphous background with the area of 
the crystalline peaks would indicate that the fraction of amorphous phase content in all 
samples was low (<10%).  
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Table 2 - Relative percentage of precipitated phases before and after 7 and 42 days of immersion, 








On soaking for 7 days, the relative weight fractions of the β-Ca2P2O7 and KCa(PO3)3 
phases decreased for all three samples, with a concomitant increase in the relative weight 
fractions of the other two phases, most notably the β-Ca(PO3)2 phase. This behaviour 
corresponds to the dissolution (loss) of the β-Ca2P2O7 and KCa(PO3)3 phases during 
soaking, with the relative increase of the other two phases. Soaking for 42 days seems to 
have resulted in a further decrease in the relative weight fraction of the KCa(PO3)3. In 
contrast, the relative weight fraction of the β-Ca2P2O7 phase increased from 7 to 42 days 
soaking, with a decrease in the weight fraction of the β-Ca(PO3)2 phase. 
The above results were confirmed by SEM analysis since the crystalline phases 
precipitated in different regions of the microstructure of the glass could be easily 
distinguished at a magnification of 4000×, as shown in Figure 3.  
Glass samples before crystallization presented a microstructure completely amorphous 
(Fig. 3A) whereas crystallized samples showed volume crystallization (Figs 3B-3D). The 
phases denoted by 1 and 2 contain only Ca and P elements, but showed different Ca/P 
ratio. The phase denoted by 3 contains all elements presented in the amorphous glass Mg, 
P, K and Ca, and the phase denoted by 4 contains only P, Ca and K elements. The areas 
denoted by 1 may correspond to β-Ca(PO3)2 and Ca4P6O19 since the Ca/P atomic ratio  was 
≅ 0.5-0.6(6). 
The areas denoted by 2 may correspond to the β-Ca2P2O7 phase, since the Ca/P atomic 
ratio was ≅ 1. The areas denoted by 3 should correspond to the glassy residual matrix since 
it is composed of all elements that were present in the mother glass; this area appears to be 
Immersion time (days) β-Ca2P2O7 β-Ca(PO3)2 KCa(PO3)3 Ca4P6O19
MK5B 0 73 18 7 2
7 50 34 5 10
42 65 26 4 5
MK5C 0 77 8 7 8
7 52 37 4 7
42 57 28 5 10
MK5E 0 70 12 9 9
7 52 26 7 15







phosphate-rich, which would correlate with this region corresponding to the residual glassy 




































Figure 3 - Micrographs obtained by SEM and EDS spectra of the labelled regions (1-4) (4000×). 
(A) Glass MK5 (B) MK5B, (C) MK5C and (D) MK5E. 
 
The specific volume of the glass MK5 and glass ceramics (MK5B, MK5C and MK5E) 
samples was shown to be 2.60 ± 0.03 g/cm3 with no statistically significant difference. 
The variation of weight loss with the immersion time is shown in Figure 4 where it may be 
observed that the range of weight loss varies from ≅ 3.0 - 4.1% after one day to 9.3 - 




























Figure 4 - Weight loss against immersion time for the studied glass ceramics. 
  
The material MK5B showed the highest dissolution among the three glass ceramics under 
study. MK5C and MK5E showed similar behaviour, i.e., a steady increased weight loss at 
early immersion times achieving about 9% on day 14, which was then kept constant until 
42 days.  
Figure 5 depicts the variation of pH of the Tris-HCl solution with immersion time. It was 
observed a slight increase on pH after half a day of immersion for all glass ceramics, 
followed by a decrease up to 42 days. The glass ceramic MK5B showed the largest 








Figure 5 - Variation of pH of the Tris solution with immersion time (standard deviation lower than 
0.04). 
 
Figure 6 shows the PO43-, K+, Mg2+ and Ca2+ ions concentration against immersion time 
for all studied glass ceramics. The concentration of PO43-, K+ and Mg2+ ions in solution had 






































concentration up to 42 days. However, for Ca2+ ion the higher release was achieved from 















Figure 6 - Ion release from the glass ceramics into Tris-HCl solution (P, Mg, K and Ca) against 
time of immersion, () MK5B, () MK5C and (∆) MK5E. 
 
The dissolution of K+ and PO43- ions was much higher compared with the other two ions, 
leading to concentrations from 350 to 1500 ppm, which may be mainly explained by the 
increased degradation with time of the KCa(PO3)3 phase, as confirmed by Rietveld 
analysis, and the residual glassy phase, as confirmed by the presence of the increasing 
Mg2+ ion concentration in the soaking solution. 
FTIR results of amorphous glass and crystallized glasses before degradation studies are 
shown in Figure 7. As expected a broad spectrum was obtained for the glass sample and 
specific functional groups were identified for glass ceramics that corresponded to 
metaphosphate and pyrophosphate, (PO3)- and (P2O7)4-. These results are in accordance 
with functional groups of the crystalline phases identified by XRD: β-Ca2P2O7, 
KCa(PO3)3, β-Ca(PO3)2 and Ca4P6O19. FTIR spectra of MK5B glass ceramic are plotted in 
Figure 8 before and after degradation testing. Since there is a strong band overlapping for 


































































with immersion time. However, comparing MK5B before immersion and after 42 days 
immersion significant band decrease could be detected mainly in the regions of 650-800 



























Figure 8 - FTIR spectra of the glass ceramic MK5B before and after immersion in Tris-HCl 
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Several authors have reported the preparation of CaO-P2O5 glass ceramics using different 
nucleating agents to promote volume crystallization(20,21). Shi and James(22)  reported the 
addition of B2O3 to study the effect on the nucleation of CaO-P2O5 glasses, James et al(20) 
reported the addition of nucleating agents such as Al2O3 and TiO2 and Abe et al.(7,23) added 
a few percentage of Na2O and TiO2, but using a different preparation route since the glass 
ceramics were prepared by sintering and crystallization of the glass powder compacts.  
In this study, glass ceramics were successfully prepared with 3.0 < O/P < 3.5 (between the 
metaphosphate (Q2) and pyrophosphate (Q1) region), using a heat treatment for 
crystallization of the CaO-P2O5 glasses with two additives that promote volume nucleation 
and the formation of bioactive and biodegradable phases. In the crystallization heat-
treatment cycles volume crystallization could only be obtained when the crystallization 
treatment was above the first crystallization peak detected by DTA. After heat treatments 
of crystallization, four phases were precipitated in the glass ceramics. One of them was 
calcium pyrophosphate β-Ca2P2O7 (β-DCP), which is reported in to be bioactive(6). The 
biocompatibility of the other three phases KCa(PO3)3, Ca4P6O19 and β-Ca(PO3)2 has not 
been clearly reported in the literature, however β-Ca(PO3)2 is considered to be non-toxic(8). 
The other two phases are also believed to be harmless since their degradation products are 
metabolized by cells. 
Dissolution studies were carried out in order to investigate the degradation of these glass-
ceramics and results confirmed that by controlling the overall composition of the initial 
glass, namely its O/P ratio, glass ceramics with high degree of degradability may be 
obtained. In fact, the level of chemical degradation observed for these materials is well-
above that reported in literature for bioactive ceramics that are clinically used, namely 
hydroxyapatite (HA), Ca10(PO4)6(OH)2 and tricalcium phosphate (TCP) Ca3(PO4)2. 
Several authors have reported that the level of calcium and phosphorus that are leached out 
from HA and TCP ceramics under similar degradation testing are usually in the range of 
6.1-0.36 ppm and 13-5.5 ppm, respectively(24). 
The glass ceramics prepared in this work seem to be capable of combining a bioactive 
behaviour in vivo, due to the bioactive and bioresorbable phases that exist in the 
microstructure, with the possibility of having good potential as drug delivery system, since 
the degradability has been shown to be significant. Further studies to examine the in vivo 
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behaviour of these materials will be conducted to assess this hypothesis. 
The ionic release profile showed that initially a high ion concentration was observed in the 
soaking solutions, particularly for phosphate groups, which tended to reach a plateau after 
12h of immersion. A relative decrease in Ca2+ ion concentration was detected after 7 days 
of immersion, which could be attributed to the precipitation of Ca-rich calcium phosphate 
phase on the samples surface, which was confirmed in block samples of the same 
composition that were immersed in the same test conditions. Further studies are now being 
conducted to determine the composition and structure of this precipitated calcium 
phosphate phase. 
The variation of pH can be correlated to the release of ionic species from glass ceramics to 
the soaking solution. In the first 12h of immersion, there was a slight increase in pH that 
was due to predominant phosphate group dissolution compared to the cationic species (see 
Fig. 6). Another stage seemed to occur from 12h to 7days where pH decreases as a result 
of the leaching of β-Ca2P2O7 and KCa(PO3)3 crystalline phases as well as of the residual 
glassy phase, as confirmed respectively by the phase quantification performed by XRD 
analysis and by the sharp increase in Mg2+ ion concentration of the soaking solution. 
The change in the relative weight fractions of the β-Ca2P2O7 and the β-Ca(PO3)2 phases 
from 0 to 7 days and from 7 to 42 days, Table 2, implies a change in the dissolution 
profiles of the materials. During the early stages of soaking (0-7 days), the β-Ca2P2O7 
phase appeared to be the most soluble phase, with the relative weight fraction decreasing 
significantly over this time period. As a result, the relative weight fraction of the β-
Ca(PO3)2 phase increased, but this does not correspond to more of this phase forming; the 
increase is based on a significant amount of the β-Ca2P2O7 being lost to dissolution. 
Correspondingly, from 7 to 42 days soaking, the Ca(PO3)2 phase showed a large decrease 
in relative weight fraction, implying that this phase was the most soluble during this time 
period . It should be noted that from 0 to 7 days the pH of the soaking solution was >7.4, 
whereas from 7 to 42 days the pH dropped to as low as 6.0; this change in pH would have 
a strong effect on the relative solubility of different calcium phosphate phases. 
It should also be noted that the glass ceramic with the greatest degradability (MK5B), 
indicated by the largest ion concentrations in the soaking solution (Fig. 6) also showed the 
biggest drop in pH (Fig. 5). The greater degradation of the material MK5B is a 







temperature used for this glass ceramic (690 ºC) most probably induced a more amorphous 




Glass ceramics with different phases, such as β-Ca2P2O7, KCa(PO3)3, β-Ca(PO3)2 and 
Ca4P6O19 can be obtained, using small additions of nucleating agents such as K2O and 
MgO. The MK5B material was shown to be the most soluble material, using a recognized 
(ISO) dissolution-testing standard. The incorporation of K2O in a glass ceramics increases 
the solubility, and offers greater flexibility in terms of tailoring the solubility to suit the 
potential biomedical application. The straightforwardness of synthesis and the ability to 
control the degradability of these calcium phosphate glass ceramics makes them potentially 
clinically helpful for promoting the regeneration of soft as well as hard connective tissue(5).  
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2.2. Crystallization studies of biodegradable CaO-P2O5 glass with MgO 
and TiO2 for bone regeneration applications 
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ABSTRACT 
CaO-P2O5 glass ceramics with small additions of MgO and TiO2 were prepared in the 
ortho- and pyrophosphate regions by powder sintering and crystallization through heat 
treatment at different temperatures determined from differential thermal analysis (DTA). 
The glass ceramics were analysed by X-ray diffraction (XRD) and it was observed that α- 
and β-Ca2P2O7 were the first phases to precipitate in the parent glass matrix at a 
temperature of 681ºC, followed by CaTi4(PO4)6 and TiP2O7 at temperatures between 703 
and 725ºC. The β-Ca2P2O7 and CaTi4(PO4)6 phases are usually considered as 
biocompatible and bioactive and therefore these glass ceramics seem to show good 
potential for bone regeneration applications. 
 
INTRODUCTION 
Although glass ceramics are conventionally obtained by controlled crystallisation of the 
parent glass, sintering and crystallisation of fine glass powders can also be used to 
fabricate these materials. The parent glass composition is usually chosen to ensure 
precipitation of desired crystalline phases(1,2). The properties of multiphase systems depend 
not only on the preparation route but also on the properties and content of each phase 
precipitated in the glass matrix(3). The aim of this work was to develop and characterize 
glass ceramics located mainly between ortho- and pyrophosphate region of the CaO-P2O5-
MgO-TiO2 system that could be used in medical applications for bone regeneration. The 
CaO-P2O5-MgO-TiO2 system was chosen based on previous studies(4). The glass ceramics 
Chapter 2.2 
52 
under study were characterised by XRD and the crystallisation process studied using DTA 
analysis. 
 
MATERIALS AND METHODS 
Glass preparation 
A calcium phosphate glass (MT13) was prepared with the composition of 
37P2O5.45CaO.5MgO.13TiO2 (mol%), by conventional melting technique at 1550°C for 
1h followed by rapid quenching in water. The frit particles were dried at 80°C and then 
pulverised in a ball mill pot to sub-10 µm using methanol as a liquid medium. The particle 
size distribution was analysed using laser diffraction (Coulter LS 230, U.K.). All 
measurements were performed in triplicate. 
 
Glass ceramic preparation 
Glass ceramic samples were prepared by powder sintering and crystallisation through heat 
treatment at different temperatures, ranging from glass transition temperature (Tg) to the 
crystallization temperature (Tc) as determined by differential thermal analysis (DTA) as 
shown in Figure 1. The DTA analysis was carried out in a DTA–50 (Shimadzu) with a 
heating rate of 15°C/min and temperature scanning up to 1200°C, using alumina powder 
(Al2O3) as reference. The pulverised glass powders were uniaxially pressed at 185 MPa to 
obtain disc shaped compacts. The discs were then heated to either 681, 703 or 725°C at a 
rate of 4ºC/min and were held at these temperatures for 1h. The resulting glass ceramics 
are referred to as MT13A, MT13B and MT13C, respectively. 
 
Materials characterization 
The density of the glass and glass ceramics was measured using the Archimedes method 
with water as the immersion liquid and all measurements were performed in triplicate. 
XRD was used to identify the crystalline phases that precipitated from the parent glass. 
The samples were ground to a fine powder and analyzed in a Siemens D 5000 
diffractometer, using flat plate geometry and CuKα radiation. Data were collected using a 
scintillation counter and a graphite monochromator, from 10 to 70°(2θ), with a step size of 
0.02º and a counting time of 5 s per step.  
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RESULTS AND DISCUSSION 
The pulverised glass particles had unimodal particle size distribution with D0.5 = 4.2 µm 
and D0.9 = 7.2 µm. All particles were below 7.2 µm. The mean density values of the glass 
ceramics MT13A, MT13B and MT13C were approximately 2.90 ± 0,03 g/cm3 with no 
statistical difference among them. 
The DTA curve obtained for the amorphous glass MT13 is shown in Figure 1 where the 
glass transition temperature (Tg) was observed at 637ºC and one doublet exothermic peak, 
attributed to crystallisation, with peak temperatures of TC1 = 750ºC and TC2 = 762ºC. The 
presence of two endothermic peaks at 1043 and 1180ºC are attributed to the residual glass 









Figure 1 - DTA curve of the 37P2O5-45CaO-5MgO-13TiO2 glass (MT13). 
 
XRD patterns of glass samples after heat treatment shown in Figure 2 revealed that the first 
phases that precipitated in the glass matrix were α- and β-Ca2P2O7 at 681ºC, with the α-
phase present in slightly higher percentage than β-phase. Furthermore, higher temperatures 
induced precipitation of CaTi4(PO4)6 and TiP2O7 phases. MT13B and MT13C glass 
ceramics showed similar phase contents, consisting of α- and β-Ca2P2O7, CaTi4(PO4)6 and 
TiP2O7. Two of these four phases, calcium pyrophosphate β-Ca2P2O7 (β-DCP) and 
CaTi4(PO4)6 are reported to be biocompatible and bioactive(5-8). Dissolution studies are 
undergoing in order to investigate the in vitro degradation of these glass ceramics. 
 
 

































Figure 2 – X-ray diffraction spectra from samples sintered at (a) 681ºC, (b) 703ºC and (c) 725ºC. 
 
CONCLUSIONS 
It is possible to induce the precipitation of crystalline phases that show different behaviour 
(α-Ca2P2O7, β-Ca2P2O7, CaTi4(PO4)6 and TiP2O7) in the CaO-P2O5-MgO-TiO2 glass 
ceramic by controlling the crystallisation conditions. 
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ABSTRACT 
This study aims to develop glass ceramics in the calcium phosphate system that exhibit 
suitable properties to be used for biomedical applications. Calcium phosphate glasses with 
the incorporation of small additions of MgO and TiO2 oxides were prepared in the pyro- 
and orthophosphate regions. The glass ceramics were prepared by a controlled powder 
sintering process through heat-treatment at different temperatures, as defined by results 
from differential thermal analysis (DTA). The composition of the crystalline phases 
precipitated in the glassy matrix as a result of heat treatments at different temperatures, 
ranging from 681 to 725ºC, was determined from X-ray diffraction data. The sequence of 
phase crystallization in the mother glass was also studied in situ using high temperature X-
ray diffraction (HT-XRD) analysis. Results showed that the first phases that precipitated in 
the glass matrix were α- and β-Ca2P2O7 at 620ºC. A small amount of CaTi4(PO4)6 
appeared at 630ºC. At 650ºC the three phases α-Ca2P2O7, β-Ca2P2O7 and CaTi4(PO4)6 
were clearly presented with a small amount of TiP2O7 and finally at 660ºC all four phases 
were observed. Glass ceramics were also characterized using Raman and X-ray 
photoelectron spectroscopy. This study demonstrates that, by altering the heat treatment 
cycle, it is possible to prepare glass ceramics in the calcium phosphate system that contains 
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different bioactive and biocompatible phases. 
 
INTRODUCTION 
Calcium phosphate glasses have been considered as prospective materials for the 
reconstruction and repair of bone as a consequence of their biocompatibility and 
bioactivity, which are of enormous interest in the development of bioabsorbable material 
for bone healing applications. Therefore, a biocompatible resorbable material with 
increased resorption rates may be useful; this rate can be high and controllable in some 
calcium phosphate glass ceramics. Due to this feature and the fact that the composition of 
glass ceramics may resemble the mineral phase of bone, calcium phosphate glass ceramics 
may be tailored to be used as a cavity filler for maxillofacial surgery or as a drug delivery 
carrier, among other applications. However, a balance between their degradation rate and 
the bone remodelling time must be considered, as some glass systems are too soluble for 
some purposes. It is well known that by modifying the composition of these glass 
ceramics, the degradation rate can be controlled, and this can be considerably reduced by 
the incorporation of some metallic oxides in the glass network, such as TiO2(1-6).  Previous 
reports of the preparation of glass and glass ceramics in the CaO-P2O5-TiO2 system have 
indicated that biocompatible and bioactive phases may be produced(7,8). With this 
composition a new family of phosphate glass ceramics appears, with a mixture of soluble 
and less soluble crystalline phases, such as β-Ca2P2O7 and CaTi4(PO4)6, respectively(9-11).  
The aim of this work is to study the crystallization of the glass in the system CaO-P2O5-
MgO-TiO2 prepared between the pyrophosphate (Q1) and orthophosphate (Q0) region (3.5 
< O/P < 4.0). A heat treatment, defined by the results obtained from differential thermal 
analysis (DTA), was used to achieve nucleation and bulk crystallization. This heat 
treatment was studied in situ using high temperature X-ray diffraction (HT-XRD). Various 
other properties of the glass ceramics were studied by Raman and X-ray photoelectron 
spectroscopy and correlated to the changes in the glass structure after heat treatment. 
 
MATERIALS AND METHODS 
Glass ceramic preparation 
The calcium phosphate glass was prepared with the composition of 37P2O5-45CaO-5MgO-
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13TiO2 in mol% (MT13) by the conventional melting technique, using the following 
analytical chemicals: CaCO3, MgHPO4.3H2O, TiO2 and H3PO4. Briefly, after water 
quenching, the glass particles were dried and then pulverized in a ball mill pot by a wet-
method using methanol to a mean particle size less than 10 µm(12). This powder was firstly 
unixially pressed at 185 MPa to obtain disc shaped compacts followed by 
sintering/crystallization cycles at different temperatures. The heat treatment temperatures 
used to obtain the glass ceramics were based on the previous Differential Thermal Analysis 
(DTA) results, as described elsewhere(12). Briefly, these results showed that the values 
obtained for glass transition temperature, Tg, was 637ºC and the onset of crystallization 
was at 726ºC. Four different heat treatment temperatures (659, 681, 703 and 725oC) that 
lay between these two values were chosen, Table 1.  
 






High temperature X-ray diffraction (HT-XRD) analysis was performed on the mother glass 
to study the sequence of phase crystallization. For HT-XRD, glass samples were analyzed 
using a Bruker D8 Advance diffractometer, with flat plate geometry and Cu-Kα radiation. 
Data were collected using a scintillation counter with primary and secondary Goebel 
mirrors from 20 to 50º (2θ), with a step size of 0.02º and a counting time of 1.7 s per step. 
The analysis was performed each 10ºC from 600 to 740 ºC with a heating rate of 4ºC/min 
and a dwell time of 45 min per scan. 
The heat-treated samples as prepared in the section 2.1. were analyzed by X-ray diffraction 
(XRD)  in order to identify and to quantify the percentage of crystalline phases that 
precipitated in the microstructure at the different treatment temperatures. For the X-ray 
diffraction measurements glass ceramics were ground to a fine powder and data were 
collected from 10 to 70º (2θ), with a step size of 0.02º and a counting time of 5 s per step. 
Satisfactory quantitative phase analysis of these samples using the Rietveld method, using 







the software GSAS, was not possible due to the complex powder patterns, in particular the 
presence of four different phases with differing peak widths/shapes, significant 
overlapping of peaks, and an amorphous phase. The weight fraction of each crystalline 
phase that precipitated for the different heat treatments was calculated from an equation 
that accounts for the scale factor of each phase and the density of each phase(13). The 
purpose of these calculations was not to determine definitive values of the phase 
compositions of these samples, as it is acknowledged that such methods make numerous 
assumptions. In particular, they will not account for varying degrees of crystallinity of the 
different phases and preferred orientation effects. However, for the purpose of following 
trends in the evolution of the crystallization of the four phases with increasing temperature 
this model is adequate. For each diffraction pattern, a background was fitted and 
subtracted, using the Bruker DIFFRACplus EVA software. The uncertainty associated with 
the composition was less than 5%. 
To identify functional groups, the glass and glass ceramic samples were analyzed by FT-
Raman spectroscopy (transmission mode) using a system 2000 FTIR spectrometer (Perkin 
Elmer). The resolution used was 4 cm-1 and the number of scans was 200 for each analysis. 
X-ray photoelectron spectroscopy (XPS) studies of the mother glass and heat-treated 
samples was conducted on a VG-Scientific ESCALAB 200A spectrometer using an 
achromatic Al (Kα) X-ray source operating at 15 KeV (300 W). All elements were 
identified from survey spectra collected over a range of 0–1300 eV with an analyzer pass 
energy of 50 eV. For deeper analysis, high-resolution spectra were recorded from 
individual peaks at 20 eV pass energy. The binding energy (BE) scales were referenced to 
the adventitious C1s BE at 285.0 eV. The peak deconvolution was performed using 
XPSPeak4.1 software. The Chi-squared test was used to validate the fitting and the null 
hypothesis (there is no difference between the fitting and the experimental curves) was 
rejected for squared-chi values higher than the critical value for P=0.05. 
 
RESULTS 
The diffraction patterns of samples heated at 659, 681, 703 and 725oC are presented on 
Figure 1. Heating the samples at 659oC (MT13NC) did not produce any crystalline phases, 
as observed by XRD, but did produce a broad background characteristic of an amorphous 
phase. Two phases were observed in samples heated at 681oC, α- and β-Ca2P2O7 
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(MT13A), and all four phases, α- and β-Ca2P2O7, CaTi4(PO4)6 and TiP2O7, were observed 
after heating at 703 and 725oC (MT13B and C). The peak positions of the CaTi4(PO4)6 
phase were shifted to slightly lower 2 theta values, by approximately 0.1-0.2º. The results 
from the calculation of the phase compositions (wt %) after A, B and C heat treatments of 
glass samples are shown in Figure 1. The two polymorphs of Ca2P2O7 in the MT13A 
samples were present in comparable amounts, and for the MT13B and MT13C samples, all 
four phases were present in approximately equal amounts.  A glassy phase appeared to be 
present in all samples, as indicated by a broad background band in the diffraction patterns. 



















Figure 1 - X-ray diffraction patterns of samples heated at 659 (a), 681 (b), 703 (c) and 725ºC (d) 
and relative percentage of precipitated phases after heat treatment A, B and C, as described in the 



























































































Hot-chamber XRD results obtained by heating the mother glass powder at 4ºC/min from 
610 to 660ºC are shown in Figure 2; for temperatures above 660oC, the diffraction patterns 
showed no differences, and are therefore excluded. The patterns revealed that the first 
phases that precipitated in the glassy matrix were α- and β-Ca2P2O7 at 620ºC and a small 
content of CaTi4(PO4)6 appeared at 630ºC. At 650ºC the three phases, i.e. α-Ca2P2O7, β-
Ca2P2O7 and CaTi4(PO4)6 were clearly present with a small content of TiP2O7 and finally at 
660ºC all four phases were observed. In terms of the sequence of crystalline phase 
formation these results were in agreement with the phase composition analysis of samples 











Figure 2 – HT-XRD pattern of mother glass (MT13) at 4ºC/min with an interval of 10ºC, ranging 
from 610-660 ºC. 
 
Raman spectra of the mother glass (MT13) and the glass ceramics are shown in Figure 3 
where a broad bands may be seen at approximately 900 and 1045 cm-1; the latter band may 
be attributed to the presence of pyrophosphate radical, P2O74-. Another specific functional 
group was identified for glass ceramic MT13B and MT13C samples that correspond to 
orthophosphate (PO43-) group, which was also present at similar wavelengths. The P2O74- 
group should be assigned to the pyrophosphate group of α- and β-Ca2P2O7 and TiP2O7, and 
the PO43- group to the CaTi4(PO4)6 phase. Generally speaking, it is usually difficult to 
distinguish the contributions of PO43- and P2O74- bands since there is a strong overlapping 
of the signal of these groups, particularly for glass ceramic samples that are not completely 
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Figure 3 – Raman spectra before (MT13) and after heat treatment A, B and C. 
 
Two Raman peaks characterize the MT13A glass ceramic, one weak peak at approximately 
738 and a strong peak at 1045 cm-1 assigned to the presence of P2O74- group, which is 
much more clearly defined than for the previous spectra due to the crystallization 
treatment. This group corresponds to the presence of Ca2P2O7 phase and is related to the P-
O-P bridges and P-O stretching, respectively(14). New bands appear for the MT13B and 
MT13C glass ceramics, around 440 cm-1 and ranging from 950-1020 and 1060-1160 cm-1. 
The bands located at around the 440 cm-1 region can be assigned to the symmetric bending 
modes of the PO4 ion, although bands below this position may also involve modes arising 
from TiO6 groups(15). The new bands located at the 1060-1160 cm-1 region can be assigned 
to the presence of the TiP2O7 phase. The Raman bands located at approximately 968, 987 
and 1008 cm-1 are assigned to the asymmetric and symmetric stretching of a P-O bond(16). 
The bands at 968 and 1008 cm-1 correspond to the PO43- group of the CaTi4(PO4)6 phase, 
and it is noteworthy to verify that higher intensity was detected for MT13C than for 
MT13B. This may be due to there being more crystalline phases in the MT13C glass 
ceramic, compared to the MT13B sample, or that the CaTi4(PO4)6 phase was more 
crystalline in the former sample. A weak band located at 777 cm-1 was also observed in 
MT13B and MT13C glass ceramics, which can be assigned to the TiO6 group, as reported 
Raman Shift/cm-1   


















by Krimi et al.(15). 
Figure 4 shows the high-resolution XPS spectra of the mother glass. Similar results were 
obtained for glass ceramics with exception for P2p and Ti2p, which present two peaks, as 
shown in Figure 5. The binding energies of the Ca2p, P2p, Mg1s, Ti2p, and O1s of the 
mother glass and glass ceramics determined from the respective high resolution spectra are 























Figure 4 - High-resolution XPS spectra of the mother glass, (a) Ca2p, (b) P2p, (c) Ti2p, (d) O1s 
and (e) Mg1s. 
 
The Ca2p peak shown in Figure 4 (a) can be deconvoluted to a doublet peak, Ca2p1 located 



































































Mg 1s (e) 
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Figure 5 – High-resolution spectra of P2p and Ti2p for glass ceramics. 
 
 
Table 2 – Binding energy of elements (P, O, Ca, Ti and Mg) detected on the mother glass and glass 






The phosphorus line on the mother glass was a single peak located at 133.5 eV, which is 
correlated to the Ca2P2O7 phase, with a full width half maximum (FWHM) of 2.25 eV 
indicating a possible overlapping peak. After heat treatment, and crystallization, new 
phosphate species appear around 136.0 eV, as shown in Figure 5. The nature of the 
chemical compound in which this element is present is not clearly understood in the 
literature, but may be attributed to a different structural environment for the P2O74- groups.  
The high-resolution spectra of Ti2p depicted in Figure 4 (c) for mother glass showed two 
doublet peaks.  The doublet peak located at 456.9 and 462.4 eV corresponds to Ti in lower 
oxidation state 3+ (Ti3+) and the doublet at 459.2 and 464.8 eV to titanium in 4+ state 
(Ti4+). The values are in accordance with NIST XPS database. After heat treatment, only 
the doublet peak corresponding to Ti4+ was detected. 
The O1s photoelectron spectrum, depicted in Figure 4 (d) provided important information 
                  P 2p                   O 1s            Ca 2p                                            Ti 2p Mg 1s
Samples P 2p(1) P 2p(2) O 1s(1) O1s(2) Ca 2p1 Ca 2p3           Ti 2p1           Ti 2p3
Ti3+ Ti4+ Ti3+ Ti4+
MT13 133.5 531.2 533.2 350.9 347.4 462.4 464.8 456.9 459.2 1304.1
MT13A 133.8 136.0 531.4 533.1 351.1 347.6 464.6 459.2 1304.5
MT13B 133.5 136.0 531.2 533.3 350.8 347.8 464.5 459.1 1304.3



























by deconvoluting the O1s spectra. In fact, the main peak located at 531.2 ± 0.3 eV was 
correlated to the pyrophosphate (P2O74-) group, as reported in the literature(17). The second 
peak was located at 533.1 ± 0.2 eV. Shih et al. reported that for glass ceramic samples the 
standard O1s peak for P-O-P bonds was located at 533.1 eV(18).  
The magnesium line, showed in Figure 4 (e) was a single peak located at 1304.0 ± 0.4 eV 
and no significant variations was observed for all samples studied.  
 
DISCUSSION 
Several authors have carried out a great deal of work on glass and glass ceramics within 
the composition of CaO-P2O5-TiO2 and realized their enormous importance for the 
development of glass ceramics with biocompatible and bioactive phases(7,8,14,19). From this 
composition, a new family of phosphate glass ceramics have been prepared in this work 
containing soluble and less soluble crystalline phases, such as β-Ca2P2O7 and CaTi4(PO4)6 
respectively.  
In the present study, glass ceramics were successfully prepared between the pyrophosphate 
(Q1) and orthophosphate (Q0) region (3.5 < O/P < 4.0). After heat treatment, four different 
crystalline phases were identified in the glass ceramic structure. Two of them, β-Ca2P2O7 
(β-DCP) and CaTi4(PO4)6 are reported to be biocompatible and bioactive, 
respectively(14,20,21). The biocompatibility of the other two phases TiP2O7 and α-Ca2P2O7 
has not been clearly reported so far in the literature. However, previous in vitro cell culture 
studies demonstrated that these materials allow the growth of MG63 osteoblast-like 
cells(22). These glass ceramics resulted in good in vitro behaviour due to the bioactive and 
biocompatible phases that exist in the microstructure.  
HT-XRD allows us to ensure that the true evolution of phases with temperature can be 
followed, as quenching/cooling of heated samples can induce artefacts. The HT-XRD 
patterns revealed that the first phases that precipitated in the glass matrix in situ were α- 
and β-Ca2P2O7 at 620ºC with a small amount of CaTi4(PO4)6 appearing at 630ºC. The 
formation of α- and β-Ca2P2O7 seems to be a simultaneous process. It is interesting to note 
that the α-polymorph is normally observed on heating β-Ca2P2O7 to temperatures greater 
than ≅1150oC but for the glass composition used in this study, it crystallizes at the same 
time as the β-polymorph, at only 620oC(23). At 650ºC the three phases α-Ca2P2O7, β-
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Ca2P2O7 and CaTi4(PO4)6 are present with a small content of TiP2O7.  
In terms of the order of the evolution of phases during heating of the mother glass, these in 
situ results are in agreement with those obtained by conventional phase analysis of samples 
subjected to different heat treatments, as the first phases precipitated were α- and β-
Ca2P2O7. The samples with heat treatment B (703ºC) and C (725ºC) consisted of 
approximately equal amounts of the four phases. However, a discrepancy occurred in the 
temperature range within which the formation of phases was observed in the two 
techniques, i.e., XRD and HT-XRD, and from the DTA observations(12). Comparing the 
results obtained from the two X-ray diffraction studies, it was observed that phase 
nucleation/crystallization (β- and α-Ca2P2O7) starts at ≅ 620ºC for HT-XRD, while 
nucleation occurred only at temperatures above 659ºC as a result of the heat treatment 
process; heat treatment at 659oC resulted in an amorphous diffraction pattern by XRD. 
Identical results were obtained for the CaTi4(PO4)6 phase, which was observed to form 
630ºC using HT-XRD, but only appeared at 703ºC after heat treatment.  It should be noted 
that heat treatments were carried out according to the results obtained from DTA 
analysis(12). In HT-XRD all phases were present at 650ºC, however from samples that were 
heat-treated, this was only achieved at 703ºC. The first crystallization temperature from 
DTA analysis was found to be ≅ 726C, which should correspond to the Ca2P2O7 phases, 
and the second crystallization temperature was ≅ 820oC to the Ti-containing phases. 
The main reason for these differences in nucleation temperature should be attributed to the 
initial size, agglomeration state and time of heat treatment at each temperature. The HT-
XRD was performed on fine loose powder packed in a holder and therefore the high 
surface area favoured a nucleation and crystallization whereas XRD was performed on 
coarse powder obtained from block samples. On the other hand 45min dwell time at each 
temperature was applied which accounted for faster phase transformation, justifying the 
lower crystallization temperature of HT-XRD compared with XRD. It is known that 
surface area plays an important role in the sintering and phase nucleation mechanisms, 
with higher surface areas inducing higher rates for both processes(24,25). It should also be 
noted that the heating profiles of the two methods are different, and are also different from 
the heating profile in the DTA analysis, as shown in Figure 6. 
The functional groups identified for glass ceramics MT13A, MT13B and MT13C by 
Raman spectroscopy correspond to the functional groups of the crystalline phases 
identified by both X-ray diffraction techniques, i.e., orthophosphate (PO43-) and 
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pyrophosphate (P2O74-). As indicated before, all functional groups that were identified by 
Raman analysis correspond to those existing in the crystalline phases α- and β-Ca2P2O7, 
TiP2O7 and CaTi4(PO4)6 and are in accordance with literature values(14,16). Also, we 
obtained in previous studies some reference data from Raman spectroscopy measurements 
of some of the pure phases crystallized in the glass ceramics, which were as follows: 1044 
and 734 cm-1 peaks for β-Ca2P2O7, 455, 960, 998 and 1009 cm-1  peaks for CaTi4(PO4)6 
and 636, 1021, 1039, 1046 and 1069 cm-1 peaks for TiP2O7. The evolution of these 
functional groups in the Raman spectra with increasing treatment temperature corresponds 
to the results obtained from the XRD analysis, whereby the TiP2O7, and CaTi4(PO4)6 









Figure 6 – Heating profiles of XRD (       ), HT-XRD (       ) and DTA (      ) analysis. 
 
A useful parameter to detect changes in the surface composition of glass and glass 
ceramics is the calcium/phosphorus atomic ratio (Ca/P). According to the oxides used for 
the mother glass preparation the theoretical value should be Ca/P= 0.60. The experimental 
value determined by quantitative XPS is around 0.59 for the mother glass, which is very 
close to the theoretical value. The binding energies for P2p, Ca2p3 and O1s observed at 
133.5, 347.1 and 531.2 eV respectively corresponded to the Ca2P2O7 phases present in the 
glass ceramics, as listed in NIST XPS database(17). The O1s XPS spectrum was 
deconvoluted into two peaks for the mother glass as well as for the glass ceramics. It is 
characteristic of a glass to possess bridging (BO) and non-bridging oxygen (NBO) groups. 
For this reason it is reasonable that the glass before heat treatment presents two distinct 
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O-M´ (M´= Mg, Ca and Ti) vibrations at higher binding energy (NBO). The binding 
energy observed for Ti highlighted the presence of two oxidation states 3+ and 4+ in 
mother glass. The mother glass showed a violet colour which in accordance to literature 
should correspond to the presence of Ti3+(26). This observation does not exclude the 
existence of Ti4+. After crystallization the colour was white which seems to indicate that 
the majority of Ti is in Ti4+ state. 
All these considerations allow one to conclude that it was possible to prepare glass 
ceramics in the calcium phosphate system that contained different bioactive and 
biocompatible phases and, by altering the heat treatment cycle, materials with different 
proprieties were obtained.  
 
CONCLUSIONS 
This work has demonstrated that depending upon the heat treatment cycle glass ceramics 
with various contents of α- and β-Ca2P2O7, CaTi4(PO4)6 and TiP2O7 phases were obtained. 
These phases are biocompatible and known to degrade at different rates in vivo which may 
be an important factor to cover several clinical applications.  
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2.4. Physicochemical degradation studies of calcium phosphate glass 
ceramic containing TiO2 and MgO oxides 
 
ABSTRACT 
The in vitro degradation behaviour of MT13B (45CaO-37P2O5-5MgO-13TiO2, mol %) 
glass ceramic in two possible physiological conditions at pH=7.4 and pH=3.0 are reported. 
The incorporation of TiO2 in the glass structure leads to the precipitation of specific 
crystalline phases in the glass matrix, namely α- and β-Ca2P2O7, TiP2O7 and CaTi4(PO4)6.  
The in vitro testing was carried out at 37ºC during periods of 42 days in pH 7.4 solution 
and during 24h in pH 3.0 solution. The degradation testing at pH 3.0 showed a higher 
weight loss compared with degradation testing at pH 7.4; the weight loss under the acidic 
condition was about ten times higher after 42 days of immersion at pH 7.4. The ionic 
release profile of Ca2+, PO43-, Mg2+ and Ti4+ showed a continuous increase in concentration 
over all immersion times for both testing solutions. At pH 7.4 the level of dissolution of 
MT13B was low, leading to the low release of ions. For Mg2+, Ca2+, PO43- after 24h of 
immersion at pH 3.0, the concentration levels were about six times higher than the levels 
after 42 days of immersion at pH 7.4. The structural changes at the surface of materials 
during degradation have been analyzed by Raman spectroscopy and scanning electron 
microscopy (SEM). Results suggest that the degradation is dependent on the medium and 
pH used in the dissolution test. This material seems to offer an attractive alternative for 
slowly resorbable materials in biomedical applications. 
 
INTRODUCTION 
The research on bioresorbable materials for tissue regeneration applications has been 
increasing significantly(1) because these materials do not require a second surgery to 
retrieve the implant, which happens to bioinert materials in many cases. However, the 
variety of available degradable biomaterials is still too restricted to cover an adequate 
range of diverse material properties(1-3). Hence, the development of new degradable 
biomaterials is currently an important research challenge in the biomaterials field. In this 
perspective, calcium phosphate glass ceramics seems to be a motivating choice for this 
purpose as their solubility can be tailored by controlling the chemical composition of the 
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base glass and choosing the correct heat treatment cycle, and thus short-term or long-term 
soluble phosphate glass ceramics may be obtained(2-6). 
Considering the solubility in the physiological environment, these materials must be seen 
as multiphase systems in which each phase has a unique degradable characteristic. The 
solubility of glass ceramics was reported to be influenced by several factors:  1) 
composition of the crystalline phases, 2) structure and density of the crystalline phases, 3) 
volume fraction of crystalline phases, and 4) grain size of crystalline phases(7-11).  
Generally the biodegradation of calcium phosphates may be caused by three major factors: 
1) physicochemical dissolution, which depends on the solubility product of the material 
and the local pH of its environment; 2) physical disintegration into small particles as a 
result of preferential chemical attack of grain boundaries, and 3) biological factors, such as 
phagocytosis(1,8,9,11). 
Calcium phosphate glass ceramics, and particularly those in the P2O5-CaO-MgO-TiO2 
system, have been demonstrated to support cell growth and differentiation in vitro and to 
provide osteoconductivity with in vivo degradation compatible with new bone formation(12-
15). The aim of this work was to evaluate the in vitro degradation behaviour of the 45CaO-
37P2O5-5MgO-13TiO2 (mol %) glass ceramic at two different physiological conditions of 
pH 7.4 and 3.0. 
 
MATERIALS AND METHODS 
Glass ceramic preparation 
Glass ceramic MT13B with the composition of 45CaO-37P2O5-5MgO-13TiO2, mol % was 
prepared by the powder sintering technique. The sintering of glass powder was performed 
according to differential thermal analysis (DTA) results of the base glass, as described 
elsewhere(16,17). Briefly, MT13 base glass was sintered at 703ºC for 1h, with a heating rate 
of 4ºC/min and naturally cooled inside the furnace. The prepared glass ceramic was then 
crushed, ground and sieved in the range of 355-425 µm. 
 
In vitro degradation studies  
The degradation testing was performed in triplicate, according the standard ISO 10993-14 




degradation products from ceramics”. Two sets of experiments were performed at different 
pH. The first set was conducted at pH 3.0 using citric acid and it was referred as extreme 
solution testing, and the second experiment was performed at pH 7.4 using Tris-HCl 
solution, referred to as simulation solution testing.  
The samples were incubated for 6, 12 and 24h in the extreme solution testing and for 7, 14, 
28 and 42 days in the simulation solution testing. At these time points, granules were 
collected by filtering (0.22 µm), washed in deionised water and dried to constant weight. 
At the end of each immersion time the pH value of the soaking solution was measured at 
37 ± 0.1ºC. A relative weight loss percentage (WL) after a certain time of immersion, t, of 
the samples was calculated from the following equation:  
 
WL= [(W0-Wt)/W0]× 100 
 
where W0 and Wt stand for initial and final weight after a specific immersion time, 
respectively.  
 
Ionic concentration measurement 
The quantitative determination of the released ions into the testing solution was measured 
using two different techniques. Calcium, magnesium and titanium ions were measured by 
flame atomic absorption spectroscopy (AAS) (GBC 90AA), whereas the phosphate ion 
concentration was measured by ultraviolet spectroscopy using the molybdenum blue 
method (Philips, Model PU 8620, UV-Vis Nir). According to this method, pyrophosphate 
groups were converted to orthophosphate by a heating procedure using sulphuric acid and 
ammonium persulphate. All results are presented as arithmetic means ± standard deviation.  
 
Materials characterization 
The granule samples were ground to a fine powder form in order to be analyzed by Raman 
spectroscopy (transmission mode) using a system 2000 FTIR spectrometer (Perkin Elmer) 
before and after the degradation testing. The resolution used was 4 cm-1 and the number of 
scans was 200. A JEOL scanning electron microscope (JSM-35C) was used to observe the 




Figure 1 shows the variation of sample weight with immersion period for both testing 
solutions. A similar trend was observed for both conditions, with a steady weight loss with 
the immersion period. After 42 days of immersion in simulation solution (pH 7.4) a weight 










Figure 1 – Weight loss percentage against immersion time for MT13B glass ceramic in: (A) 
simulation and (B) extreme testing condition. 
 
The variation in pH of the two testing solutions with immersion time is shown in Figure 2. 
In the pH 7.4 testing solution (Figure 2A), no significant variation of pH could be observed 
while for the extreme testing solution (Figure 2B) a slight increase in pH was observed up 








































































Figures 3 and 4 show the variation of the Ca2+, PO43-, Mg2+ and Ti4+ ionic concentrations 
against immersion time in both testing solutions. The variation of the concentration of the 
ions released in both testing solutions showed a similar trend, continuously increasing 
throughout the immersion time but with a lower degradation rate for most of the ions 
analyzed at pH 7.4. The level of concentration attained for Ca2+ was higher than the PO43- 
in both testing solutions. 
Despite the very short immersion time used in the extreme condition, when compared to 
the physiological pH 7.4 solution, a higher amount of each ion was released into the former 








Figure 3 – Ca2+ () and PO43- () ion concentration in simulation A) and extreme testing solution 









Figure 4 – Mg2+ () and Ti4+ () ion concentration in simulation (A) and extreme testing solution 
(B) against immersion time. 
 

























































A (pH 7.4) 
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shown in Figure 5. SEM observations revealed important differences in the progress of 
surface degradation in both solutions. A much more degraded surface was observed in the 
experiment conducted at pH 3.0 just after 6h (Fig. 5C) of immersion compared with the 













Figure 5 –SEM images of the glass ceramic MT13B before (A) and after immersion in simulation 
(B) and extreme testing solution (C). 
 
Raman spectra of MT13B glass ceramic before and after degradation testing in both 












Figure 6 – Raman spectra of the glass ceramic MT13B before and after immersion during 7 and 42 
days at pH 7.4 and 1 day at pH 3.0. 
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Comparing MT13B spectrum before and after immersion, significant band changes could 
be detected mainly in the region of 900-1160 cm-1, as observed in the detailed figure. The 
associated vibrations correspond to ortho- and pyrophosphate groups(18,19), correlated to 
those crystalline phases existing in the glass ceramic, namely α- and β-Ca2P2O7, TiP2O7 
and CaTi4(PO4)6. After soaking for 42 days in pH 7.4 solution a slightly decrease was 
observed in the band located at 1069 cm-1 correlated to the P2O74- groups present in the 
TiP2O7 phase. Strong band changes were observed for 24h soaking in pH 3.0 solution, and 
this was more pronounced in the band located at approximately 1045 cm-1 assigned to the 
presence of P2O74- groups. 
 
DISCUSSION 
In this work a base glass with the composition 45CaO-37P2O5-5MgO-13TiO2 (mol %) was 
prepared and converted into a glass ceramic by a sintering technique. As previously 
published, four crystalline phases were precipitated in the glass matrix, α and β−Ca2P2O7 
(α- and β-DCP), CaTi4(PO4)6 (CTP) and TiP2O7 (TP) phases(18,20). Two of them, β-DCP 
and CTP, are reported to be biocompatible, with the former being present in commercial 
graft materials such as Bioresorb® and Vitoss®(21). However, the biocompatibility of the 
other two phases is not clearly reported in the literature. Literature also reports that CTP is 
almost insoluble in normal physiological conditions, although Ploska et al.(22) state that the 
presence of TP as a minor phase in the CTP matrix can improve its degradation rate. β-
DCP was reported as not dissolving in distilled water(23), while for TP and α-DCP pure 
phases no results have been reported so far in the literature.  
Despite the controversy regarding the in vitro acellular tests for assessing biodegradation, 
since calcium phosphate ceramics can either undergo chemical and/or cellular degradation 
in vivo conditions, a number of authors believe these experiments can give insights about 
the biodegradation behaviour of MT13B glass ceramic(10,11,13).  
The chemical degradation studies, following the ISO 10993, consisted of two tests. The 
first test, an extreme solution conducted at pH 3.0 used a citric acid buffer solution that 
mimics the acid environment produced by osteoclasts. Literature reports that direct pH 
measurements of the extracellular fluid from bone-resorbing cells showed that the pH was 
as low as 3(24). The second test simulates a more frequently encountered in vivo pH 7.4 
using TRIS-HCl buffer. Using these two soaking mediums with different pH values the 
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mechanisms of degradation, which may not be the same at normal body pH as it is for the 
case of extremely low pH 3.0, were also evaluated. 
When performing the degradation testing at pH 3.0, a higher weight loss was quantified as 
expected. Based on the weight loss obtained, the dissolution of MT13B at pH 7.4 is 
comparable to HA as reported in the literature, being relatively insoluble in neutral solution 
and readily soluble in acid solution(25,26). One of relevant parameter on the study of glass 
dissolution kinetics is the kind of medium used. The pH and ionic strength of the medium 
have an important role on the rate at which the glasses dissolve(10,27). In fact, the weight 
loss observed after 24h of immersion at pH 3.0 was about ten times higher than in 42 days 
at pH 7.4. SEM observations also showed that the superficial degradation mechanism is 
higher in acidic solution than in neutral solution. As compared with the granule samples 
before soaking, no significant superficial degradation changes were observed in the 
granules samples after soaking at pH 7.4. 
The ionic release profiles found from MT13B dissolution showed a continuous increase in 
the concentration of the evaluated ions over all immersion time, even though their 
appeared to be a reduction in the dissolution rate in the extreme testing solution after about 
12 hours. It should be noted that the degradation of MT13B during the immersion time 
revealed the presence of a residual glassy phase probably at grain boundaries. In fact, 
despite not detecting a chemical phase containing magnesium in MT13B glass ceramic 
composition by XRD, Mg2+ ions were continuously released into both testing solutions 
over the entire immersion time evaluated.  
At pH 7.4 minor dissolution of MT13B occurred leading to low release of ions. As a 
consequence of higher dissolution of MT13B at lower pH testing solution, increases in ion 
concentration release were observed. For Mg2+, Ca2+, PO43- after 24h of immersion at pH 
3.0, the ion concentration levels were about six times higher than the values observed after 
42 days of immersion at pH 7.4. 
The citric acid (CA) used as soaking medium in the pH 3.0 testing solution may also have 
had a role in the dissolution process. Literature reports that the presence of CA may inhibit, 
stimulate or have no effect on the dissolution of some calcium phosphate materials, 
depending on the type of molecular events that take place on crystal surface(28-31). The fact 
that Ti4+ concentration levels detected on test solution at pH 3.0 were lower compared to 
those observed with the pH 7.4 solution should be related to the interaction of Ti4+ with 




surface. As a consequence of this, similar molar levels of Ca2+ and PO43- were attained in 
this extreme pH medium, in contrast to what happened at pH 7.4. This interaction might 
also be followed by protonation of citrate groups in the surface contributing to the small 
pH increase observed with this solution. The residual glassy phase should also have 
contributed to the release of some Ti4+ ions into both testing solutions. 
The different degradation behaviours in terms of pH changes observed for the 2 testing 
solutions is a response to the cations and anions released into each solution as a result of 
partial dissolution of some chemical phases present in the MT13B glass ceramic. 
 
CONCLUSIONS 
The results obtained in this work demonstrated that the degradation of MT13B material is 
dependent on the medium and pH used in the dissolution test. A stronger degradation was 
observed using pH 3.0 citric acid buffer solution compared to the normal physiological pH 
7.4, where is the glass ceramic was relatively insoluble, with results that were comparable 
to hydroxyapatite. Therefore, opportunities exist to use this material as a bone graft in 
certain clinical applications, such as cranioplasty, where relative slow resorption and 
replacement by bone is quite acceptable. 
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